Phillip J. Koo, MD, Banner MD Anderson Cancer Center, Phoenix, Arizona discusses how theranostics will change the way physicians treat prostate cancer by helping select the appropriate patient for therapies and showing which ones respond.
Keywords: prostate cancer, theranostics, nuclear medicine, therapeutics, diagnostic agent
ABOUT THE AUTHOR
Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM).
